
Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQRDJhcFVNX1RfaU5pcFVXd1VYOEJicVNQYWhvRmJtZVBqa09JVGlTYmRQSU53RWFDVXVhajh5ekRvM2dEaHhWemFIMmpFOW1fVlk4aXJQeDFsNEhpTHVpWHNDanU0WHhfR1dmanZFZFV3X3ZDZWpfcHRyaW1meXVELXF1SmRUTmFaU01zbEpiZlJTQ3pzelZWNmhERGtRVDljcWtsZHZESTVZUHBoZzRDTGhSLXJUWXpSVU1DejYxYlRtMFh3Wm1Qbm1zLVZIRGxY?oc=5" target="_blank">Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD</a>&nbsp;&nbsp;<font color="#6f6f6f">Applied Clinical Trials</font>


